Tangram Doses First Participant in Phase 1 Trial of TGM-148
Tangram said it dosed the first participant in a Phase 1 trial of its bleeding disorder drug TGM-148.
Tangram said it dosed the first participant in a Phase 1 trial of its bleeding disorder drug TGM-148.